
Combining TRIAC (3,3',5-triiodothyroacetic acid) with novel selective THRB agonists like VK2809 to achieve optimal thyroid hormone receptor activation in brain while minimizing peripheral hyperthyroidism through tissue-selective receptor subtype targeting
